These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 26888181)

  • 21. Fibroblast growth factor 23 and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease.
    Kanbay M; Nicoleta M; Selcoki Y; Ikizek M; Aydin M; Eryonucu B; Duranay M; Akcay A; Armutcu F; Covic A
    Clin J Am Soc Nephrol; 2010 Oct; 5(10):1780-6. PubMed ID: 20576822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Race on the Association of Mineral Metabolism With Heart Failure: the Multi-Ethnic Study of Atherosclerosis.
    Robinson-Cohen C; Shlipak M; Sarnak M; Katz R; Peralta C; Young B; Hoofnagle AN; Szklo M; Ix JH; Psaty BM; de Boer IH; Kestenbaum B; Bansal N
    J Clin Endocrinol Metab; 2020 Apr; 105(4):e1144-51. PubMed ID: 31760429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fibroblast Growth Factor 19 Levels Predict Subclinical Atherosclerosis in Men With Type 2 Diabetes.
    Hu J; Liu Z; Tong Y; Mei Z; Xu A; Zhou P; Chen X; Tang W; Zhou Z; Xiao Y
    Front Endocrinol (Lausanne); 2020; 11():282. PubMed ID: 32528406
    [No Abstract]   [Full Text] [Related]  

  • 24. Fibroblast growth factor-23 and incident coronary heart disease, heart failure, and cardiovascular mortality: the Atherosclerosis Risk in Communities study.
    Lutsey PL; Alonso A; Selvin E; Pankow JS; Michos ED; Agarwal SK; Loehr LR; Eckfeldt JH; Coresh J
    J Am Heart Assoc; 2014 Jun; 3(3):e000936. PubMed ID: 24922628
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum fibroblast growth factor 21 is predictive of combined cardiovascular morbidity and mortality in patients with type 2 diabetes at a relatively short-term follow-up.
    Lenart-Lipińska M; Matyjaszek-Matuszek B; Gernand W; Nowakowski A; Solski J
    Diabetes Res Clin Pract; 2013 Aug; 101(2):194-200. PubMed ID: 23768789
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma fibroblast growth factor 23, parathyroid hormone, 25-hydroxyvitamin D3, and risk of heart failure: a prospective, case-cohort study.
    di Giuseppe R; Buijsse B; Hirche F; Wirth J; Arregui M; Westphal S; Isermann B; Hense HW; Dierkes J; Boeing H; Stangl GI; Weikert C
    J Clin Endocrinol Metab; 2014 Mar; 99(3):947-55. PubMed ID: 24423292
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community.
    Hagström E; Hellman P; Larsson TE; Ingelsson E; Berglund L; Sundström J; Melhus H; Held C; Lind L; Michaëlsson K; Arnlöv J
    Circulation; 2009 Jun; 119(21):2765-71. PubMed ID: 19451355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FGF-23 levels are associated with vascular calcification, but not with atherosclerosis, in hemodialysis patients.
    Turan MN; Kircelli F; Yaprak M; Sisman AR; Gungor O; Bayraktaroglu S; Ozkahya M; Asci G; Floege J; Ok E
    Int Urol Nephrol; 2016 Apr; 48(4):609-17. PubMed ID: 26865177
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [MORPHOGENETIC PROTEINS--FIBROBLAST GROWTH FACTOR AND KLOTHO, IN THE SERA OF PATIENTS WITH CHRONIC RENAL DISEASE].
    Milovanova LY; Kozlovskaya LV; Markina MM; Milovanova SY; Borisov AA; Mukhin NA; Fomin VV; Moiseev SV
    Klin Med (Mosk); 2015; 93(12):32-8. PubMed ID: 27149811
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FGF-23 as a predictor of renal outcome in diabetic nephropathy.
    Titan SM; Zatz R; Graciolli FG; dos Reis LM; Barros RT; Jorgetti V; Moysés RM
    Clin J Am Soc Nephrol; 2011 Feb; 6(2):241-7. PubMed ID: 20966122
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patients with autosomal dominant polycystic kidney disease have elevated fibroblast growth factor 23 levels and a renal leak of phosphate.
    Pavik I; Jaeger P; Kistler AD; Poster D; Krauer F; Cavelti-Weder C; Rentsch KM; Wüthrich RP; Serra AL
    Kidney Int; 2011 Jan; 79(2):234-40. PubMed ID: 20944552
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FGF-23/Vitamin D Axis in Type 1 Diabetes: The Potential Role of Mineral Metabolism in Arterial Stiffness.
    Llauradó G; Megia A; Cano A; Giménez-Palop O; Simón I; González-Sastre M; Berlanga E; Fernández-Veledo S; Vendrell J; González-Clemente JM
    PLoS One; 2015; 10(10):e0140222. PubMed ID: 26462160
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of fibroblast growth factor-23 in peripheral vascular calcification in non-diabetic and diabetic hemodialysis patients.
    Inaba M; Okuno S; Imanishi Y; Yamada S; Shioi A; Yamakawa T; Ishimura E; Nishizawa Y
    Osteoporos Int; 2006 Oct; 17(10):1506-13. PubMed ID: 16896512
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Change of cardiovascular risk associated serologic biomarkers after gastric bypass: A comparison of diabetic and non-diabetic Asian patients.
    Wei JH; Lee MH; Lee WJ; Chen SC; Almalki OM; Chen JC; Wu CC; Lee YC
    Asian J Surg; 2022 Nov; 45(11):2253-2258. PubMed ID: 35012855
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The impact of vitamin D status on the relative increase in fibroblast growth factor 23 and parathyroid hormone in chronic kidney disease.
    Taal MW; Thurston V; McIntyre NJ; Fluck RJ; McIntyre CW
    Kidney Int; 2014 Aug; 86(2):407-13. PubMed ID: 24429404
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Soluble klotho and mortality: the Ludwigshafen Risk and Cardiovascular Health Study.
    Brandenburg VM; Kleber ME; Vervloet MG; Larsson TE; Tomaschitz A; Pilz S; Stojakovic T; Delgado G; Grammer TB; Marx N; März W; Scharnagl H
    Atherosclerosis; 2015 Oct; 242(2):483-9. PubMed ID: 26298739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Parathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: dependent or independent risk factors?
    Anderson JL; Vanwoerkom RC; Horne BD; Bair TL; May HT; Lappé DL; Muhlestein JB
    Am Heart J; 2011 Aug; 162(2):331-339.e2. PubMed ID: 21835295
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FGF-23 levels in patients with AKI and risk of adverse outcomes.
    Leaf DE; Wolf M; Waikar SS; Chase H; Christov M; Cremers S; Stern L
    Clin J Am Soc Nephrol; 2012 Aug; 7(8):1217-23. PubMed ID: 22700885
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Parathormone Levels Are Independently Associated with the Presence of Left Ventricular Hypertrophy in Patients with Coronary Artery Disease.
    Aceña Á; Pello AM; Carda R; Lorenzo Ó; Gonzalez-Casaus ML; Blanco-Colio LM; Martín-Ventura JL; Palfy J; Orejas M; Rábago R; Gonzalez-Parra E; Mahíllo-Fernández I; Farré J; Egido J; Tuñón J
    J Nutr Health Aging; 2016; 20(6):659-64. PubMed ID: 27273357
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The combination of soluble tumor necrosis factor receptor type 1 and fibroblast growth factor 21 exhibits better prediction of renal outcomes in patients with type 2 diabetes mellitus.
    Chang LH; Hwu CM; Chu CH; Lin YC; Huang CC; You JY; Chen HS; Lin LY
    J Endocrinol Invest; 2021 Dec; 44(12):2609-2619. PubMed ID: 33834419
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.